Jump to main content
Jump to site search

Issue 13, 2011
Previous Article Next Article

Magnetoliposome for alendronate delivery

Author affiliations

Abstract

Encapsulation into liposomes has been developed in order to allow protection of therapeutical agents against enzymatic degradation, and to reduce doses and toxic side effects. Selective, targeted and controlled release of the drug out of the lipid vesicle is still, however, difficult to achieve. Meanwhile, thanks to their magnetic properties, superparamagnetic iron oxide (SPIO) nanoparticles have also been considered as good delivery vehicles after grafting a therapeutic drug on their surface. A combination of both properties (magnetic targeting and drug encapsulation) is evaluated to deliver an anticancer drug : alendronate, an hydroxymethylene bisphosphonate molecule. γ-Fe2O3 nanocrystals grafted with alendronate were tested with or without liposome encapsulation, with and without magnetic field, on three human cancer cell lines, MDA-MB231, A431 and U87-MG. Cytotoxicity was measured as well as drug internalization. While results were not identical on the three cell lines with the different formulations, an effective 100% cytotoxic effect could only be achieved with alendronate grafted-SPIO entrapped into liposomes and exposed to a magnetic field.

Graphical abstract: Magnetoliposome for alendronate delivery

Back to tab navigation

Publication details

The article was received on 05 Jan 2011, accepted on 25 Jan 2011 and first published on 21 Feb 2011


Article type: Paper
DOI: 10.1039/C1JM00060H
J. Mater. Chem., 2011,21, 4813-4820

  •   Request permissions

    Magnetoliposome for alendronate delivery

    F. Benyettou, I. Chebbi, L. Motte and O. Seksek, J. Mater. Chem., 2011, 21, 4813
    DOI: 10.1039/C1JM00060H

Search articles by author

Spotlight

Advertisements